| Literature DB >> 35701508 |
James R Fernando1, Glenn D Walker1, Thomas Kwan-Soo Park1, Peiyan Shen1, Yi Yuan1, Coralie Reynolds1, Eric C Reynolds2.
Abstract
Assessment of enamel subsurface lesion remineralisation is essential for the evaluation of novel remineralisation technologies. The gold standard to assess subsurface mineral gain of enamel lesions is transverse microradiography (TMR). However, some studies have utilised surface microhardness (SMH) to evaluate efficacy of remineralisation agents. The aim of this study was to assess remineralisation of enamel subsurface lesions using TMR and SMH after in vitro treatment with calcium-containing technologies, and to test correlation between the TMR and SMH measurements. The parameters obtained from the TMR and SMH analyses of enamel subsurface remineralisation were not significantly correlated. Furthermore, the enamel subsurface remineralisation as measured by TMR was significantly correlated with the water-soluble calcium concentration of the remineralisation products. Scanning electron microscopy revealed surface precipitates formed by specific remineralisation treatments obfuscated accurate assessment of remineralisation by SMH. It was concluded that TMR is a more appropriate method for analysis of enamel subsurface remineralisation, and that SMH values of remineralised enamel should be interpreted with caution. Using TMR the level of remineralisation (%R) by the different technologies was CPP-ACP/F (31.3 ± 1.4%); CPP-ACP (24.2 ± 1.4%); CaSO4/K2HPO4/F (21.3 ± 1.4%); f-TCP/F (20.9 ± 1.0%); Nano-HA/F (16.3 ± 0.3%); Nano-HA (15.3 ± 0.6%) and F alone control (15.4 ± 1.3%).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35701508 PMCID: PMC9197824 DOI: 10.1038/s41598-022-13905-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Remineralisation treatments: active ingredients, fluoride concentration and dilution factor in artificial saliva (AS).
| Group | Remineralisation solution | Manufacturer | Active ingredientsa | Total fluoride (ppm) |
|---|---|---|---|---|
| A | Artificial Saliva (AS) | – | – | – |
| B | AS + Colgate Total | Colgate | 0.22% w/w NaF | 1000 |
| C | AS + Tooth Mousse | GC | CPP-ACP | – |
| D | AS + Tooth Mousse Plus | GC | CPP-ACP | 900 |
| 0.2% w/w NaF | ||||
| E | AS + Age Defying | Arm & Hammer | 0.24% w/w NaF | 1100 |
| Calcium Sulfate | ||||
| Dipotassium phosphate | ||||
| F | AS + Apagard m-Plus | Sangi | Nano HA | – |
| G | AS + Remin Pro | Voco | Nano HA | 1450 |
| 0.32% w/w NaF | ||||
| H | AS + Clinpro Tooth Crème | 3 M ESPE | f-TCP | 950 |
| 0.21% w/w NaF |
CPP-ACP casein phosphopeptide-amorphous calcium phosphate, Nano-HA nanohydroxyapatite, f-TCP functional tricalcium phosphate.
Water-soluble calcium concentrations in diluted treatment solutions measured with ion chromatography.
| Remineralisation solution | Water-soluble Ca (mM) |
|---|---|
| AS | 0.50 |
| AS + Colgate Total | 0.61 |
| AS + Tooth Mousse | 24.75 |
| AS + Tooth Mousse Plus | 25.05 |
| AS + Age Defying | 2.39 |
| AS + Apagard M-Plus | 1.61 |
| AS + Remin Pro | 0.70 |
| AS + Clinpro Tooth Crème | 1.05 |
Surface microhardness recovery of subsurface enamel lesions by treatment solutions.
| Remineralisation solution | VHNs* | VHNdα | VHNrβ | %SMHRγ |
|---|---|---|---|---|
| AS | 319.34 ± 9.75 | 61.41 ± 8.92 | 71.49 ± 8.40a | 3.92 ± 1.44a |
| AS + Colgate Total | 325.64 ± 12.03 | 59.68 ± 8.39 | 82.42 ± 7.86ab | 8.61 ± 1.90b |
| AS + Tooth Mousse | 328.37 ± 5.14 | 57.85 ± 9.60 | 81.08 ± 11.37ab | 8.87 ± 2.27b |
| AS + Tooth Mousse Plus | 326.26 ± 10.11 | 59.68 ± 11.44 | 79.54 ± 10.55ab | 7.48 ± 1.59b |
| AS + Age Defying | 325.59 ± 25.43 | 64.78 ± 8.26 | 132.69 ± 33.3c | 27.47 ± 12.13c |
| AS + Apagard m-Plus | 315.70 ± 8.98 | 60.69 ± 9.95 | 97.19 ± 12.89bc | 14.38 ± 2.21c |
| AS + Remin Pro | 318.49 ± 9.27 | 67.82 ± 7.41 | 78.86 ± 7.40ab | 4.43 ± 2.06a |
| AS + Clinpro Tooth Crème | 316.83 ± 21.70 | 63.24 ± 7.03 | 78.61 ± 7.47ab | 6.12 ± 1.30ab |
*VHNs: Kruskal–Wallis test—no difference across treatments (p > 0.05).
αVHNd: ANOVA—no difference across treatments (p > 0.05).
βVHNr: ANOVA—significant difference across treatments (p < 0.0001).
γ%SMHR: ANCOVA—main effects model for treatment and VHNs–VHNd as covariate.
Significant differences across treatments (p < 0.0001) with significant effect of VHNs–VHNd as covariate (p = 0.042).
abcSame superscripts in column denote means that are not significantly different (p > 0.05). All differences between treatments were measured using pairwise comparisons with a Sidak adjustment.
Figure 1Representative enamel surface SEM images of treated subsurface lesions (× 5000 magnification).
Remineralisation of enamel subsurface lesions by treatment solutions.
| Remineralisation solution | LDd (µm)* | LDd–LDr (µm)α | ZDd (vol% min µm)β | ZDd–ZDr (vol% min µm)γ | %Rδ |
|---|---|---|---|---|---|
| AS | 89.65 ± 2.93 | 1.79 ± 2.22 | 1989.59 ± 276.35 | 226.23 ± 37.45 | 11.37 ± 1.26 |
| AS + Colgate Total | 88.98 ± 3.62 | 4.01 ± 2.52 | 2236.00 ± 284.69 | 344.02 ± 57.79ab | 15.37 ± 1.28ab |
| AS + Tooth Mousse | 91.69 ± 1.62 | 3.87 ± 1.45 | 2294.78 ± 164.23 | 554.56 ± 35.40 | 24.21 ± 1.39 |
| AS + Tooth Mousse Plus | 92.44 ± 1.18 | 4.04 ± 0.86 | 2469.07 ± 134.93 | 773.96 ± 58.06 | 31.33 ± 1.38 |
| AS + Age Defying | 89.65 ± 2.39 | 1.11 ± 2.52 | 2137.87 ± 342.92 | 451.07 ± 46.65c | 21.26 ± 1.39c |
| AS + Apagard m-Plus | 89.46 ± 2.70 | 2.08 ± 1.88 | 2270.39 ± 218.99 | 347.75 ± 28.65ad | 15.34 ± 0.58ad |
| AS + Remin Pro | 87.80 ± 2.23 | 1.79 ± 2.03 | 2250.13 ± 253.76 | 365.84 ± 37.99bd | 16.27 ± 0.31bd |
| AS + Clinpro Tooth Crème | 88.51 ± 3.74 | 2.32 ± 3.25 | 2157.42 ± 274.03 | 450.38 ± 49.65c | 20.93 ± 0.96c |
*LDd: ANOVA—no difference between products (p = 0.062, p > 0.05).
αLDd–LDr: ANCOVA—main effects model treatment and LDd as covariate. No difference between products (p > 0.05). Effect of LDd significant (p < 0.0001).
βZDd: ANOVA—no difference between products (p > 0.05).
γZDd–ZDr: ANCOVA—main effects treatment and ZDd as covariate. Pairwise comparisons with Sidak adjustment. Highly significant differences between products (p < 0.0001). Effect of ZDd significant (p < 0.0001).
abcdsame superscripts in column denote means that are not significantly different (p > 0.05). Differences between all other means highly significant (p < 0.0001).
δ%R: ANCOVA—main effects model untransformed values with treatment and ZDd as covariate. Differences across treatment highly significant (p < 0.0001) and effect of ZDd also significant (p = 0.02).
abcdSame superscripts in column denote means that are not significantly different (p > 0.05). Differences between all other means highly significant (p < 0.0001). All differences between treatments were measured using pairwise comparisons with a Sidak adjustment.
Figure 2Representative transverse microradiographs of treated enamel subsurface lesions.
Correlations between %R and %SMHR, and between %R and bioavailable calcium.
| %R (treatment means) | %R (samples) | |
|---|---|---|
| Spearman's Rho | 0.301 | 0.246 |
| Sig | > 0.05 | > 0.05 |
| N | 8 | 56 |
| Spearman's Rho | 0.857 | – |
| Sig | < 0.01 | – |
| N | 8 | – |